Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash from Financing Activities (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Cash from Financing Activities for 11 consecutive years, with -$52000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 106.64% to -$52000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$8.1 million through Dec 2025, down 104.78% year-over-year, with the annual reading at -$8.1 million for FY2025, 104.78% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$52000.0 at Cartesian Therapeutics, down from -$38000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $124.5 million in Q3 2024, with the low at -$24.8 million in Q3 2023.
  • Average Cash from Financing Activities over 5 years is $12.6 million, with a median of $783000.0 recorded in 2024.
  • The sharpest move saw Cash from Financing Activities tumbled 4150.49% in 2023, then skyrocketed 28779.87% in 2024.
  • Over 5 years, Cash from Financing Activities stood at $21.2 million in 2021, then plummeted by 97.11% to $612000.0 in 2022, then soared by 2200.82% to $14.1 million in 2023, then plummeted by 94.44% to $783000.0 in 2024, then tumbled by 106.64% to -$52000.0 in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$52000.0, -$38000.0, and $60000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.